Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Jin Ook Chung, Seon-Young Park, Dong Hyeok Cho, Dong Jin Chung & Min Young Chung. (2021) Relationship Between Fibroblast Growth Factor 19 and Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity 14, pages 4715-4721.
Read now
Read now
Jacek Rysz, Anna Gluba-Brzózka, Dimitri P Mikhailidis & Maciej Banach. (2015) Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease. Expert Opinion on Investigational Drugs 24:5, pages 603-610.
Read now
Read now
Articles from other publishers (35)
Yanjun Zhang, Guimei Li, Feifei Xiao, Bang Wang, Jianchang Li, Xiuhong Jia, Yan Sun & Hongye Chen. (2023) Relationship between serum fibroblast growth factor 19 and vascular endothelial growth factor and soluble klotho protein in type 1 diabetic children. BMC Pediatrics 23:1.
Crossref
Crossref
Haoyu Tian, Shuairan Zhang, Ying Liu, Yifan Wu & Dianbao Zhang. (2023) Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges. International Journal of Molecular Sciences 24:5, pages 4583.
Crossref
Crossref
Özen ÖZ GÜL & Soner CANDER. (2022) Evaluation of sitagliptin therapy on the levels of fibroblast growth factor-19 (FGF19) in patients with Type 2 diabetes. Turkish Journal of Internal Medicine 4, pages 34-40.
Crossref
Crossref
Meng-Nan Yang, Rong Huang, Xin Liu, Ya-Jie Xu, Wen-Juan Wang, Hua He, Guang-Hui Zhang, Tao Zheng, Fang Fang, Jian-Gao Fan, Fei Li, Jun Zhang, Jiong Li, Fengxiu Ouyang & Zhong-Cheng Luo. (2022) Fibroblast Growth Factor 19 in Gestational Diabetes Mellitus and Fetal Growth. Frontiers in Endocrinology 12.
Crossref
Crossref
Ryan A. Lafferty, Finbarr P.M. O’Harte, Nigel Irwin, Peter R. Flatt & Victor A. Gault. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
301
343
.
Raffaella Maria Gadaleta & Antonio Moschetta. (2021) Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver. Journal of Hepatology 75:6, pages 1440-1451.
Crossref
Crossref
Jingyi Hu, Zhiwen Liu, Yue Tong, Zubing Mei, Aimin Xu, Pengcheng Zhou, Xiaoyan Chen, Weili Tang, Zhiguang Zhou & Yang Xiao. (2020) Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes. Frontiers in Endocrinology 11.
Crossref
Crossref
Emmanuel Somm & François R Jornayvaz. (2018) Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives. Endocrine Reviews 39:6, pages 960-989.
Crossref
Crossref
Dana Friedrich, Hanns-Ulrich Marschall & Frank Lammert. (2018) Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial. BMC Gastroenterology 18:1.
Crossref
Crossref
Maximilian Bielohuby, Martin Bidlingmaier & Uwe Schwahn. (2018) Control of (pre)-analytical aspects in immunoassay measurements of metabolic hormones in rodents. Endocrine Connections 7:4, pages R147-R159.
Crossref
Crossref
Jing Zhang, Huating Li, Hu Zhou, Li Fang, Jingjing Xu, Han Yan, Shuqin Chen, Qianqian Song, Yinan Zhang, Aimin Xu, Qichen Fang, Yang Ye & Weiping Jia. (2017) Lowered fasting chenodeoxycholic acid correlated with the decrease of fibroblast growth factor 19 in Chinese subjects with impaired fasting glucose. Scientific Reports 7:1.
Crossref
Crossref
A. V. Sazhin, A. I. Khusyainova & V. A. Petukhov. (2017) Surgical management of diabetes mellitus: future outlook. Endoskopicheskaya khirurgiya 23:1, pages 46.
Crossref
Crossref
Dandan Guan, Lidan Zhao, Daiwen Chen, Bing Yu & Jie Yu. (2016) Regulation of fibroblast growth factor 15/19 and 21 on metabolism: in the fed or fasted state. Journal of Translational Medicine 14:1.
Crossref
Crossref
Javier Donate-Correa, Ernesto Martín-Núñez, Nayra Pérez Delgado, Mercedes Muros de Fuentes, Alberto Ortiz Arduan, Carmen Mora-Fernández & Juan F. Navarro González. (2016) Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes. Cytokine & Growth Factor Reviews 28, pages 71-77.
Crossref
Crossref
Daniel Jahn, Dominic Sutor, Donata Dorbath, Johannes Weiß, Oliver Götze, Johannes Schmitt, Heike M. Hermanns & Andreas Geier. (2016) Farnesoid X receptor-dependent and -independent pathways mediate the transcriptional control of human fibroblast growth factor 19 by vitamin A. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1859:2, pages 381-392.
Crossref
Crossref
Daniel Jahn, Monika Rau, Heike M. Hermanns & Andreas Geier. (2015) Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease. Cytokine & Growth Factor Reviews 26:6, pages 625-635.
Crossref
Crossref
LINGLING HU & LANXIANG CONG. (2015) Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer. Oncology Reports 34:5, pages 2683-2691.
Crossref
Crossref
Hirotaka Nagamatsu, Jun Teishima, Keisuke Goto, Hiroyuki Shikuma, Hiroyuki Kitano, Koichi Shoji, Shogo Inoue & Akio Matsubara. (2015) FGF19 promotes progression of prostate cancer. The Prostate 75:10, pages 1092-1101.
Crossref
Crossref
David P Sonne, Morten Hansen & Filip K Knop. (2014) MECHANISMS IN ENDOCRINOLOGY: Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. European Journal of Endocrinology 171:2, pages R47-R65.
Crossref
Crossref
Julian R. F. Walters. (2014) Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nature Reviews Gastroenterology & Hepatology 11:7, pages 426-434.
Crossref
Crossref
Olga Renner, Simone Harsch, Silke Matysik, Dieter Lütjohann, Gerd Schmitz & Eduard F Stange. (2014) Upregulation of hepatic bile acid synthesis via fibroblast growth factor 19 is defective in gallstone disease but functional in overweight individuals. United European Gastroenterology Journal 2:3, pages 216-225.
Crossref
Crossref
Marlene WewalkaMary-Elizabeth PattiCorinne BarbatoSander M. Houten & Allison B. Goldfine. (2014) Fasting Serum Taurine-Conjugated Bile Acids Are Elevated in Type 2 Diabetes and Do Not Change With Intensification of Insulin. The Journal of Clinical Endocrinology & Metabolism 99:4, pages 1442-1451.
Crossref
Crossref
Geneviève Marcelin, Young-Hwan Jo, Xiaosong Li, Gary J. Schwartz, Ying Zhang, Nae J. Dun, Rong-Ming Lyu, Clémence Blouet, Jaw K. Chang & Streamson ChuaJr.Jr.. (2014) Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. Molecular Metabolism 3:1, pages 19-28.
Crossref
Crossref
Dongyu Wang, Wenjing Zhu, Jieming Li, Chongyou An & Zilian Wang. (2013) Serum Concentrations of Fibroblast Growth Factors 19 and 21 in Women with Gestational Diabetes Mellitus: Association with Insulin Resistance, Adiponectin, and Polycystic Ovary Syndrome History. PLoS ONE 8:11, pages e81190.
Crossref
Crossref
Qichen Fang, Huating Li, Qianqian Song, Wenjing Yang, Xuhong Hou, Xiaojing Ma, Junxi Lu, Aimin Xu & Weiping Jia. (2013) Serum Fibroblast Growth Factor 19 Levels Are Decreased in Chinese Subjects With Impaired Fasting Glucose and Inversely Associated With Fasting Plasma Glucose Levels. Diabetes Care 36:9, pages 2810-2814.
Crossref
Crossref
Yaping Hao, Jian Zhou, Mi Zhou, Xiaojing Ma, Zhigang Lu, Meifang Gao, Xiaoping Pan, Junling Tang, Yuqian Bao & Weiping Jia. (2013) Serum Levels of Fibroblast Growth Factor 19 Are Inversely Associated with Coronary Artery Disease in Chinese Individuals. PLoS ONE 8:8, pages e72345.
Crossref
Crossref
Shu Feng, Olga Dakhova, Chad J. Creighton & Michael Ittmann. (2013) Endocrine Fibroblast Growth Factor FGF19 Promotes Prostate Cancer Progression. Cancer Research 73:8, pages 2551-2562.
Crossref
Crossref
Masaaki Miyata, Tatsuya Hata, Hiroki Yamakawa, Tatehiro Kagawa, Kouichi Yoshinari & Yasushi Yamazoe. (2012) Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19. The Journal of Steroid Biochemistry and Molecular Biology 132:1-2, pages 41-47.
Crossref
Crossref
Frank G. Schaap. (2012) Role of fibroblast growth factor 19 in the control of glucose homeostasis. Current Opinion in Clinical Nutrition and Metabolic Care 15:4, pages 386-391.
Crossref
Crossref
Sanjeev S Pattni, Gordon W Brydon, Tracy Dew & Julian R F Walters. (2012) Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid Diarrhea. Clinical and Translational Gastroenterology 3:7, pages e18.
Crossref
Crossref
Fatih Eren, Ramazan Kurt, Fatih Ermis, Ozlen Atug, Nese Imeryuz & Yusuf Yilmaz. (2012) Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clinical Biochemistry 45:9, pages 655-658.
Crossref
Crossref
Matthew J. Potthoff, Steven A. Kliewer & David J. Mangelsdorf. (2012) Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes & Development 26:4, pages 312-324.
Crossref
Crossref
Silke Matysik, Josefine Martin, Margarita Bala, Max Scherer, Andreas Schäffler & Gerd Schmitz. (2011) Bile acid signaling after an oral glucose tolerance test. Chemistry and Physics of Lipids 164:6, pages 525-529.
Crossref
Crossref
Matthew J. Potthoff, Jamie Boney-Montoya, Mihwa Choi, Tianteng He, Nishanth E. Sunny, Santhosh Satapati, Kelly Suino-Powell, H. Eric Xu, Robert D. Gerard, Brian N. Finck, Shawn C. Burgess, David J. Mangelsdorf & Steven A. Kliewer. (2011) FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway. Cell Metabolism 13:6, pages 729-738.
Crossref
Crossref
Tim C. M. A. Schreuder, Hendrik A. Marsman, Martin Lenicek, Jochem R. van Werven, Aart J. Nederveen, Peter L. M. JansenFrank G. Schaap. (2010) The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. American Journal of Physiology-Gastrointestinal and Liver Physiology 298:3, pages G440-G445.
Crossref
Crossref